Cargando…
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations
There is growing recognition that immunotherapy is likely to significantly improve health outcomes for cancer patients in the coming years. Currently, while a subset of patients experience substantial clinical benefit in response to different immunotherapeutic approaches, the majority of patients do...
Autores principales: | Dobbin, Kevin K., Cesano, Alessandra, Alvarez, John, Hawtin, Rachael, Janetzki, Sylvia, Kirsch, Ilan, Masucci, Giuseppe V., Robbins, Paul B., Selvan, Senthamil R., Streicher, Howard Z., Zhang, Jenny, Butterfield, Lisa H., Thurin, Magdalena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109653/ https://www.ncbi.nlm.nih.gov/pubmed/27891226 http://dx.doi.org/10.1186/s40425-016-0179-0 |
Ejemplares similares
-
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
por: Masucci, Giuseppe V., et al.
Publicado: (2016) -
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
por: Masucci, Giuseppe V., et al.
Publicado: (2017) -
Immunotherapy biomarkers 2016: overcoming the barriers
por: Gulley, James L., et al.
Publicado: (2017) -
Immune monitoring technology primer: Single Cell Network Profiling (SCNP)
por: Hawtin, Rachael E., et al.
Publicado: (2015) -
A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
por: Butterfield, Lisa H, et al.
Publicado: (2008)